Superworth

Black Diamond Therapeutics profit margin BDTX

Gross, operating and net profit as a share of revenue over the last twelve months, from 2025.

Net margin, 12 months
n/m
a quarter missing
Peer median
11.1%

Black Diamond Therapeutics' net margin over the last twelve months can't be worked out yet: a quarter of its results is missing from our data.

Profit margin over time

OperatingNet

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearNet marginOperating margin
FY202532.0%17.9%
FY2024n/an/a
FY2023n/an/a
FY2022n/an/a
FY2021n/an/a
FY2020n/an/a
FY2019n/an/a
FY2018n/an/a

Quarter by quarter

QuarterEndedNet margin, 12 monthsChange on a yearOperating margin
Q2 FY26n/an/an/a
Q1 FY26n/an/an/a
Q4 FY2532.0%n/a17.9%
Q3 FY2530.7%n/a16.9%
Q2 FY2520.6%n/a6.7%
Q1 FY257.3%n/a−5.7%
Q4 FY24n/an/an/a
Q3 FY24n/an/an/a
Q2 FY24n/an/an/a
Q1 FY24n/an/an/a
Q4 FY23n/an/an/a
Q3 FY23n/an/an/a

Against its peers

Companies in Healthcare nearest Black Diamond Therapeutics' size, closest first, today.

CompanyProfit margin
BDTXBlack Diamond Therapeuticsn/a
KEQUKewaunee Scientific3.0%
ICCCImmucell2.6%
LFVNLifevantage2.8%
SPROSpero Therapeutics15.7%
PDEXPro DEX17.6%
PLXProtalix BioTherapeutics23.5%
APTAlpha Pro Tech6.8%
NATRNatures Sunshine Products3.7%
ELMDElectromed15.3%
UTMDUtah Medical Products29.0%
Peer median11.1%

What the profit margin tells you

Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).

Compare within an industry. 10% is superb for a retailer and poor for a software company.

More on Black Diamond Therapeutics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.